CXCL9 and myopathy: Interestingly, the treatment with vemurafenib significantly restored the levels of eotaxin (CCL11) (Fig. 3C), an eosinophil chemoattractant (Rankin et al., 2000), and reduced the levels of monokine induced by γ interferon (MIG/CXCL9) (Fig. 3D), an important chemokine in inflammatory myopathies expressed by macrophages and T cells (Paparo, 2019).